Acuta Capital Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Acuta Capital Partners’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-580,000	Closed	-$3.96M	–	47
2022 Q1	$3.96M	Buy	+580,000	New	+$3.99M	1.85%	18
2021 Q3	–	Sell	-561,011	Closed	-$4.42M	–	50
2021 Q2	$3.78M	Sell	561,011 -533,989	-49%	-$4.24M	1.51%	24
2021 Q1	$9.9M	Buy	1,095,000 +389,782	+55%	+$3.15M	3.57%	4
2020 Q4	$4.71M	Hold	705,218	–	–	1.28%	29
2020 Q3	$3.55M	Sell	705,218 -1,047,000	-60%	-$7.62M	0.97%	30
2020 Q2	$14.2M	Sell	1,752,218 -921,500	-34%	-$8.12M	4.09%	7
2020 Q1	$20.9M	Buy	2,673,718 +1,048,718	+65%	+$8.06M	10.15%	1
2019 Q4	$12.3M	Buy	+1,625,000	New	+$8.58M	3.04%	10

Other funds holding AVDL

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Acuta Capital Partners's AVDL Position: Q2 2022 in Review

Acuta Capital Partners sold out of Avadel Pharmaceuticals (AVDL) in Q2 2022, closing a stake of 580,000 shares — an estimated $3.96M sold.

Acuta Capital Partners first reported a position in AVDL in Q4 2019 and held it in 8 quarters. The position peaked at $20.9M in Q1 2020. 82 funds tracked by Wall St. Rank hold AVDL as of Q2 2022.

Acuta Capital Partners reported no remaining Avadel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Acuta Capital Partners sold 580,000 Avadel Pharmaceuticals shares in Q2 2022, an estimated $3.96M.
Acuta Capital Partners first reported a position in Avadel Pharmaceuticals in Q4 2019 and held it in 8 quarters.
Acuta Capital Partners's Avadel Pharmaceuticals position peaked at $20.9M in Q1 2020.
82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2022.

Based on Acuta Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.